{"id":"W1595175397","doi":"","title":"Abstract 16194: PCSK9 Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid Treatment Strategies in Patients at High CVD Risk: ODYSSEY OPTIONS I","year":2014,"lang":"en","type":"article","venue":"","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Université du Québec à Chicoutimi","funders":"","keywords":"Alirocumab; Medicine; Atorvastatin; PCSK9; Rosuvastatin; Clinical endpoint; Regimen; Statin; Ezetimibe; Population; Urology; Internal medicine; Tolerability; Randomization; Evolocumab; Randomized controlled trial; Pharmacology; Gastroenterology; Adverse effect; Apolipoprotein B; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001510071,0.000669207,0.001339163,0.0003590748,0.0002222819,0.001091538,0.0006068728,0.0007579511,0.01181555],"category_scores_gemma":[0.001230466,0.0002937112,0.001359887,0.00029273,0.0006421871,0.0009794034,0.0006787265,0.002299363,0.0005633002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007547238,"about_ca_system_score_gemma":0.001109873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009498019,"about_ca_topic_score_gemma":0.00311721,"domain_scores_codex":[0.9994954,0.0002578461,0.0000461799,0.00008154562,0.0000711411,0.00004779969],"domain_scores_gemma":[0.9994592,0.0001450519,0.0001233636,0.00002367315,0.00003689604,0.0002117692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7900656,0.007116997,0.001532971,0.003562568,0.002124837,0.00008322096,0.0001816103,0.0009244449,0.0071388,0.001391442,0.004927689,0.1809499],"study_design_scores_gemma":[0.8548123,0.123536,0.007142914,0.0006786624,0.002518776,0.000145945,0.0001308966,0.00122257,0.001614774,0.0007955679,0.00736086,0.00004081447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9287055,0.04722596,0.001605458,0.005027066,0.001100573,0.002158307,0.002025312,0.0001581462,0.01199371],"genre_scores_gemma":[0.972315,0.01495499,0.00257611,0.002928463,0.0005987896,0.001459697,0.0008219084,0.00002474972,0.004320295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01181555,"threshold_uncertainty_score":0.03952694,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01459777445760022,"score_gpt":0.2761123750888265,"score_spread":0.2615146006312263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}